Format:
Online-Ressource
ISSN:
2567-689X
Content:
Abstract: Antiplatelet therapy is considered essential for secondary prevention of ischemic heart disease. After percutaneous coronary intervention (PCI), temporary dual antiplatelet therapy (DAPT), a combination consisting of aspirin and an oral P2Y12 receptor blocker, is recommended. In the long term, this strategy results in more bleeding than antiplatelet therapy with aspirin alone. Therefore, to reduce bleeding, an increasing trend has been to keep DAPT as short as clinically acceptable, after which aspirin monotherapy is continued. Another option to diminish bleeding is to discontinue aspirin at the moment of DAPT cessation after PCI, and to continue on P2Y12 blocker monotherapy. This survey reviews the evidence on P2Y12 blocker monotherapy. Some clinical guidance will be provided on when and in whom P2Y12 inhibitor monotherapy may be applied after DAPT cessation following PCI.
In:
volume:123
In:
number:02
In:
year:2023
In:
pages:159-165
In:
Thrombosis and haemostasis, Stuttgart : Thieme, 1976-, 123, Heft 02 (2023), 159-165, 2567-689X
Language:
English
DOI:
10.1055/s-0042-1755330
URN:
urn:nbn:de:101:1-2023032312061418490105
URL:
https://doi.org/10.1055/s-0042-1755330
URL:
https://nbn-resolving.org/urn:nbn:de:101:1-2023032312061418490105
URL:
https://d-nb.info/1284215814/34